Why Lumateperone Matters
Lumateperone is an antipsychotic that barely touches dopamine D2 receptors. At the 42 mg dose, it occupied about 39% of striatal D2 receptors in patients with schizophrenia, where most antipsychotics need 60% or more. Cortical 5-HT2A occupancy was above 80% after a single 7 mg dose. The label also describes partial agonist activity at D2 and moderate serotonin transporter binding. So akathisia ran close to placebo in every program, parkinsonism-type events were near placebo outside the adjunctive MDD trials, prolactin barely moved, and short-term weight, glucose and lipid changes matched placebo.
It is approved for three things. Schizophrenia was first (2019), and relapse prevention in schizophrenia was added in April 2026. Bipolar I and II depression followed in December 2021, as monotherapy or added to lithium or valproate. In November 2025 it added adjunctive treatment of major depressive disorder. The bipolar II indication is the reason to know this drug. It and quetiapine are the only two antipsychotics with positive trial evidence across both bipolar I and bipolar II depression.
Sedation is the main side effect (24% vs 10% on placebo in the schizophrenia trials). Effect sizes in schizophrenia are small. There is no approved use and no published trial data in mania, and the drug is brand-only and expensive, so expect prior authorizations. Doses below and above 42 mg lost in the pivotal trials, so you cannot dial it up for more effect or down for less sedation.
Reach for lumateperone when metabolic risk, weight, prolactin or akathisia is what limits your other options. It starts at its full dose on day one and needs no titration. Do not expect it to be the strongest drug for acute psychosis, and expect to manage sedation rather than restlessness.
Part 1: Indications
FDA-Approved Uses
- Schizophrenia (adults), including prevention of relapse (added April 2026)
- Depressive episodes of bipolar I or II disorder (adults), as monotherapy and as adjunctive therapy with lithium or valproate
- Major depressive disorder, adjunctive to an antidepressant (adults)
Not approved: acute mania or mixed episodes, bipolar maintenance (relapse prevention is approved only in schizophrenia), patients under 18, and dementia-related psychosis (this carries the class boxed warning).
Off-Label / Emerging
- Depression with mixed features, in unipolar or bipolar illness (one positive placebo-controlled trial, below)
The Evidence by Indication
Schizophrenia. Two 4-week placebo-controlled trials in the label were positive but modest. The placebo-subtracted PANSS difference was 5.8 points in Study 1 (95% CI 10.5 to 1.1) and 4.2 in Study 2 (CI 7.8 to 0.6). In both, only 42 mg separated from placebo: 84 mg in Study 1 and 28 mg in Study 2 did not. Across the wider program, three of four trials were positive. The failed one was marred by a high placebo response (its risperidone arm failed too), and the effect size in the large placebo-controlled trial was about 0.3. For relapse prevention, Study 3 (the trial behind the April 2026 approval) took 228 patients who were stable after 18 weeks of open-label 42 mg and randomized them to stay on it or switch to placebo for up to 26 weeks. Relapse was 16.4% on lumateperone and 38.6% on placebo (hazard ratio 0.37).
Bipolar depression, monotherapy. In the pivotal trial (Calabrese et al., Am J Psychiatry 2021; bipolar I n=301, bipolar II n=76), lumateperone 42 mg beat placebo on the MADRS by 4.6 points (CI 6.3 to 2.8), an effect size of 0.56. Response was 51.1% vs 36.7% and remission 39.9% vs 33.5%. A post-hoc analysis found a larger effect in bipolar II (0.81) than in bipolar I (0.49), which is hypothesis-generating and not proof. A second monotherapy trial was negative and has not been published in full. Take the effect as moderate and real, with one failed trial behind it.
Bipolar depression, added to lithium or valproate. The effect is smaller: 2.4 MADRS points over placebo (CI 4.4 to 0.4), an effect size of about 0.27. The 28 mg arm did not separate. This is a legitimate add-on, but a modest one.
Depression with mixed features (off-label). One 6-week trial (Durgam et al., J Clin Psychopharmacol 2025) enrolled 383 adults with unipolar or bipolar depression and DSM-5 mixed features. Lumateperone 42 mg beat placebo by 5.7 MADRS points (effect size 0.64), with benefit visible by day 15 and remission of 38.5% vs 19.9%. No mania or hypomania emerged. It is the first placebo-controlled trial of lumateperone in mixed depression and still needs independent replication.
MDD, adjunctive. Two 6-week trials (Studies 6 and 7) enrolled adults who had less than 50% improvement after at least six weeks of an SSRI, SNRI or bupropion. Adding lumateperone 42 mg beat placebo by 4.9 MADRS points (CI 6.38 to 3.44) in Study 6 and 4.5 (CI 6.03 to 3.02) in Study 7. There is no head-to-head comparison with generic aripiprazole or quetiapine in my sources, which matters because those are far cheaper.
The pivotal trials ran 4 to 6 weeks, and the bipolar and MDD programs have no randomized discontinuation data in the label. Nothing in the evidence tells you how long to keep it going once the episode has remitted. Make that decision on clinical grounds and revisit it.
Who Is a Good Candidate?
- A patient in whom weight gain, dyslipidemia, hyperglycemia or hyperprolactinemia is the reason other antipsychotics failed or are off the table
- A patient who developed akathisia or parkinsonism on aripiprazole, brexpiprazole, cariprazine, lurasidone or a D2 blocker
- Bipolar II depression, or bipolar I depression where tolerability is the deciding factor
- A patient who needs to start at full dose without a titration schedule
Who Is a Poor Candidate?
- A patient in acute, severe psychosis where you need your most effective agent; the schizophrenia effect sizes are small
- A patient whose main problem is mania or a mixed episode; there is no indication and no published trial data
- A patient who cannot tolerate daytime sedation or must drive or operate machinery early in treatment
- A patient on any CYP3A4 inducer, such as carbamazepine, phenytoin or rifampin; the label says to avoid the combination
- A patient for whom cost or prior authorization is prohibitive and a generic would do
Part 2: Mechanism
The label states plainly that the mechanism for these uses is unknown, and suggests it could be mediated through 5-HT2A antagonism combined with partial agonism at D2. What is measured:
- 5-HT2A antagonist: the highest-affinity target (Ki 0.54 nM), with greater than 80% cortical occupancy after a single 7 mg dose.
- D2 partial agonist, low occupancy: Ki 32 nM. Striatal D2 occupancy was about 12% after 7 mg and 39% after 2 weeks at 42 mg in patients. That fits the rarity of parkinsonism, prolactin elevation and akathisia.
- Serotonin transporter binding: Ki 33 nM, with inhibition of serotonin uptake at IC50 150 nM. The label flags this as the reason SSRI and SNRI combinations need extra monitoring.
- D1, D4 and alpha-1A/1B binding: moderate (Ki 41 nM for D1, 100 nM or lower for the others). The alpha-1 binding fits the dizziness and orthostasis.
- Little muscarinic or histaminergic binding in vitro, so the receptor table does not explain why sedation is the leading side effect.
Pharmacokinetics. Oral bioavailability is only about 4.4%. Peak levels come 1 to 2 hours after a dose, and a high-fat meal lowers Cmax by 33% and delays Tmax by about an hour while raising AUC by 9%, so food is optional. It is 97.4% protein bound, extensively metabolized (more than twenty metabolites, through UGT, aldo-keto reductase and several CYP enzymes including CYP3A4), and has a terminal half-life of about 18 hours after IV dosing. Steady state arrives in about 5 days. Between-patient variability is large (coefficients of variation for Cmax and AUC of 68% to 97%), so two patients on the same 42 mg can have very different exposure.
In vitro, lumateperone showed little to no inhibition of CYP1A2, 2C9, 2C19, 2D6 or 3A4 and no induction of CYP1A2, 2B6 or 3A4. It did not change midazolam levels.
Lumateperone is the opposite of cariprazine kinetically. It reaches steady state in about 5 days and clears in days, so a dose change or a stop shows its effect quickly.
Part 3: Before You Start: Workup and Candidacy
Use the standard atypical antipsychotic baseline, as the label asks. The clean short-term numbers do not exempt this drug.
| Assessment | Why |
|---|---|
| Weight / BMI, waist | The label says to monitor weight at baseline and frequently thereafter |
| Fasting glucose or HbA1c | Label: assess fasting plasma glucose before or soon after starting |
| Fasting lipid panel | Label: obtain before or soon after starting, then periodically |
| CBC | Needed if there is a history of low WBC or drug-induced leukopenia or neutropenia; otherwise not routine |
| Blood pressure (supine and standing) | Orthostasis risk, greatest early; extra care in older adults, dehydration, antihypertensives, cardiovascular or cerebrovascular disease |
| Sodium | If an older adult is on or starting an SSRI or SNRI: the combination can add hyponatremia risk |
| LFTs / Child-Pugh class | Moderate or severe hepatic impairment changes the dose |
| Fall risk | Label: assess at start and periodically if the patient has conditions or drugs that add to somnolence or orthostasis |
| AIMS (movement scale) | Baseline involuntary-movement exam; repeat periodically |
| ECG | Not routine. QTc rose 4.9 ms at 42 mg (upper bound of the 90% CI 8.9 ms). Reserve for cardiac history or other QT-prolonging drugs |
| Pregnancy test | In persons of childbearing potential |
Ask about seizure history, swallowing problems, recent myocardial infarction or unstable cardiovascular disease (these patients were excluded from premarketing trials), and every drug the patient takes that touches CYP3A4 or serotonin (see Part 8). Ask about antidepressant history if you are using it for MDD or bipolar depression, because the suicidality boxed warning applies.
Part 4: How to Start and Dose
| Parameter | Value |
|---|---|
| Formulations | Capsules 42 mg / 21 mg / 10.5 mg (once daily, with or without food) |
| All indications | 42 mg once daily. No titration needed |
| Strong CYP3A4 inhibitor | 10.5 mg once daily |
| Moderate CYP3A4 inhibitor | 21 mg once daily |
| CYP3A4 inducers | Avoid |
| Hepatic impairment | Mild (Child-Pugh A): usual dose. Moderate (B) or severe (C): 21 mg once daily |
| Renal impairment | No dose adjustment in the label |
| Pediatric | Safety and effectiveness not established |
| Boxed warnings | Dementia-related psychosis mortality; suicidal thoughts and behaviors (antidepressant class) |
One Dose
The label dose is 42 mg for every indication. The trials explain why there is no ladder: 28 mg lost in Studies 2 and 5, and 84 mg lost in Study 1. So you do not start low, step up, or push past 42 mg for a partial response.
Timing and Food
Any time of day works, with or without food. Sedation is the main early problem, and the sponsor moved from morning to evening dosing in later studies, after which the sedation numbers improved. Start at bedtime. A meal lowers the peak by a third without changing total exposure, so taking it with food is a reasonable tolerability move, though not required for absorption.
If the Patient Is Too Sedated
Your options are narrower than with most drugs. Move the dose to bedtime, review other sedating drugs, and give it a few weeks. Dropping to 21 mg is not supported: 28 mg did not beat placebo in the trials, and 21 mg is labeled only for CYP3A4 inhibitors and liver impairment. If sedation is intolerable at 42 mg, that is usually a reason to switch drugs.
Starting in Specific Settings
- Bipolar depression: 42 mg alone, or 42 mg with continued lithium or valproate. The adjunctive trial used patients who stayed on the mood stabilizer.
- MDD: 42 mg added to the current antidepressant, which continues. The trials enrolled adults with inadequate response to one or two antidepressant courses.
- Schizophrenia: 42 mg from day one. The relapse-prevention design used 42 mg throughout.
Switching From Another Antipsychotic
There is no label cross-taper schedule. Because lumateperone needs no titration and reaches steady state in about 5 days, the usual approach is to start 42 mg and taper the old drug over roughly one to two weeks, watching for additive sedation and orthostasis. This is common practice and not a label instruction. The usual reason to switch is metabolic, away from olanzapine or quetiapine.
Dose Adjustments and Special Populations
- CYP3A4: reduce to 21 mg with a moderate inhibitor and 10.5 mg with a strong inhibitor. Avoid inducers.
- Hepatic: 21 mg once daily in moderate or severe impairment. Exposure (AUC) was 2.4 times higher in Child-Pugh B and 1.8 times higher in C.
- Renal: no label adjustment. Exposure was not higher in mild or moderate impairment, and was 1.5 times higher in severe impairment with a confidence interval that included no change.
- Geriatric: no separate dose. The schizophrenia and MDD trials enrolled no one 65 or older; in bipolar depression, 6% of treated patients were 65 to 74 and none were older.
Part 5: Monitoring
Label instructions are general, with no fixed schedule. The one below follows ordinary practice for atypical antipsychotics.
| Parameter | Baseline | Follow-up |
|---|---|---|
| Weight / BMI | ✓ | Frequently early (monthly for 3 months), then every 3 months |
| Fasting glucose / HbA1c | ✓ | ~3 months, then annually, sooner if weight climbs |
| Lipids | ✓ | ~3 months, then annually |
| Sedation, dizziness, driving | ✓ | Every visit in the first weeks |
| Blood pressure / orthostatics | ✓ | Early visits, and when other BP-lowering drugs change |
| Suicidality and mood | ✓ | Closely in the first months and after dose changes (boxed warning) |
| EPS / AIMS | ✓ | Periodically |
| CBC | Only with prior leukopenia | Through the first few months; stop for ANC under 1000/mm3 |
| Sodium | If on an SRI and older | If symptomatic or after adding an SRI |
| Prolactin | Not routine | Only if symptomatic; prolactin rose in 2% vs 0% in the adjunctive bipolar trial |
The open-label extension numbers are reassuring but uncontrolled. Mean weight change was about -2 kg at day 175 and -3.2 kg at day 350 in stable schizophrenia, about 0 kg at 6 months in bipolar depression, and -0.16 kg at 26 weeks in MDD. In the one-year schizophrenia study, fasting glucose shifted from normal to high in 8% and HbA1c reached 6.5% or higher in 5% of those starting below it. Keep monitoring.
Part 6: Side Effects and How to Manage Them
No single adverse reaction caused discontinuation in more than 2% of patients in any program. Most complaints are early and related to sedation, dizziness or the gut. The rates below are drug vs placebo from the label tables.
Sedation and Somnolence
This is the leading side effect: 24% vs 10% in schizophrenia, 13% vs 3% in bipolar depression, and 12% vs 2% in adjunctive MDD. It also carries the label's driving and machinery caution.
- Management: bedtime dosing, with a meal if helpful, and a review of other sedatives and alcohol. Warn patients not to drive until they know how it affects them. See Part 4 for why dose reduction is not a good lever.
Dizziness and Orthostasis
Dizziness was 8% vs 4% in monotherapy bipolar depression, 11% vs 2% with lithium or valproate, 17% vs 5% in adjunctive MDD, and 5% vs 3% in schizophrenia. Formal orthostatic hypotension was infrequent (0.7% vs 0% in schizophrenia; 6.6% vs 6.2% in MDD, where the placebo rate was almost the same), and syncope was rare. Orthostatic hypotension was 0% vs 0% in the bipolar depression trials.
- Management: rise slowly, stay hydrated, check standing BP, and review antihypertensives, and counsel again when treatment restarts after a gap. Falls are a labeled risk where somnolence and postural hypotension coexist.
Nausea, Dry Mouth and GI
Nausea ran 8% to 9% vs 3% to 5% across programs. Dry mouth was 6% vs 2% in schizophrenia and 13% vs 3% in MDD. Diarrhea (5% vs 1% in MDD) and vomiting (3% to 4%) also appear.
- Management: taking it with food, sugar-free gum or lozenges for dry mouth. Most patients tolerate these.
Headache, Fatigue, Tremor
Headache was 14% vs 8% in monotherapy bipolar depression and 19% vs 13% in MDD. Fatigue was 8% vs 2% and tremor 4% vs under 1% in the MDD trials.
Extrapyramidal Symptoms and Akathisia
EPS-related events were 6.7% vs 6.3% in schizophrenia, 1.3% vs 1.1% in monotherapy bipolar depression, and 4% vs 2.3% with lithium or valproate. Scale changes (Simpson-Angus, Barnes, AIMS) were near zero. In the MDD add-on trials, EPS-type events were higher at 5% vs 0.8% (tremor, bradykinesia, muscle spasm and similar), while akathisia and restlessness combined were 1% vs 0.8%. Acute dystonia is a labeled possibility in the first days, mainly in young males.
- Management: if parkinsonism or dystonia appears, an anticholinergic is appropriate. Keep standard tardive dyskinesia surveillance.
Metabolic (Weight, Glucose, Lipids)
In the placebo-controlled trials, changes in weight, fasting glucose and lipids matched placebo in schizophrenia, bipolar depression and MDD. The long-term data are uncontrolled (Part 5). Keep the monitoring in Part 5, since the long-term data are uncontrolled.
Cardiovascular and Other
- QTc: a 4.9 ms placebo-corrected increase at 42 mg and 15.8 ms at 126 mg (three times the dose). Not a defining concern.
- Lab changes: creatine phosphokinase elevations (4% vs 1%) and transaminase increases (2% vs 1%) in schizophrenia.
- Hyperprolactinemia: rare (2% vs 0% in one trial).
- Postmarketing: skin burning sensation has been reported.
Part 7: Toxicity, Overdose, and Boxed Warnings
Lumateperone carries two. First, increased mortality in elderly patients with dementia-related psychosis. Across 17 placebo-controlled trials of antipsychotics (modal duration 10 weeks), deaths ran about 4.5% vs 2.6% on placebo, a risk 1.6 to 1.7 times higher, mostly cardiovascular or infectious. Lumateperone is not approved for dementia-related psychosis. Second, suicidal thoughts and behaviors, a warning it carries because it is used for depression: in pooled antidepressant trials the drug-placebo difference was 14 additional cases per 1,000 patients under 18 and 5 per 1,000 aged 18 to 24, with 1 fewer per 1,000 at 25 to 64 and 6 fewer per 1,000 at 65 and older. Safety and effectiveness have not been established in pediatric patients. Monitor closely early and after dose changes.
Contraindication and Other Serious Risks
- Hypersensitivity to lumateperone or any component is the only contraindication. Reactions have included pruritus, rash and urticaria.
- Cerebrovascular events in dementia-related psychosis: a higher incidence of stroke and TIA, including fatal stroke, compared with placebo.
- Neuroleptic malignant syndrome: hyperpyrexia, rigidity, delirium and autonomic instability, with possible CK elevation, rhabdomyolysis and renal failure. Stop the drug and treat supportively.
- Tardive dyskinesia: can appear after brief treatment at low doses or after stopping. Highest risk in older women. Reassess need periodically; consider stopping if signs appear.
- Leukopenia, neutropenia, agranulocytosis: discontinue if ANC falls below 1000/mm3 and monitor until recovery.
- Seizures, dysphagia, body temperature dysregulation: use cautiously with seizure history or aspiration risk, and warn against overheating and dehydration, particularly with strenuous exercise, heat or anticholinergic drugs.
- Cognitive and motor impairment: caution about driving and hazardous machinery.
Overdose
There is no specific antidote. Provide supportive care with close medical supervision and monitoring, and consider multiple-drug involvement. Poison Help (1-800-222-1222) or a toxicologist can advise.
Part 8: Drug Interactions
Lumateperone is mostly on the receiving end of interactions. CYP3A4 changes the dose, and the serotonin transporter binding changes the monitoring.
| Interaction | Effect | Risk | Action |
|---|---|---|---|
| CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) | Rifampin cut lumateperone AUC by 98% and Cmax by 92% | HIGH | Avoid. Carbamazepine is the one you will meet in bipolar patients |
| Strong CYP3A4 inhibitors (itraconazole, ketoconazole, clarithromycin, ritonavir) | Itraconazole raised AUC 3.8-fold and Cmax 3.2-fold | HIGH | Lumateperone 10.5 mg once daily |
| Moderate CYP3A4 inhibitors (diltiazem, verapamil, erythromycin, fluconazole) | Diltiazem raised AUC 2.3-fold and Cmax 1.9-fold | MODERATE | Lumateperone 21 mg once daily |
| SSRIs, SNRIs and other serotonin reuptake inhibitors | No clinically significant interaction in the MDD trials, but SERT activity may add SRI-type adverse reactions (serotonin syndrome, hyponatremia) | MODERATE | Increase monitoring, especially sodium in older adults |
| CNS depressants (alcohol, benzodiazepines, opioids, other sedating drugs) | Additive sedation and impaired coordination | MODERATE | Counsel; limit alcohol |
| Antihypertensives | Additive orthostasis | LOW | Monitor standing BP |
| Lithium, valproate | Valproate (a UGT inhibitor) and probenecid produced no clinically significant interaction; lithium and valproate were the background drugs in the adjunctive bipolar trial, and no lithium interaction study is in the label | LOW | No pharmacokinetic adjustment; expect more dizziness (11% vs 2% in the adjunctive trial) |
| CYP3A4 substrates (midazolam) | No clinically significant change in midazolam levels | NONE | No adjustment |
In a bipolar patient who already takes carbamazepine, lumateperone is the wrong choice. Lurasidone is contraindicated with it too, and quetiapine loses most of its exposure, so either change the carbamazepine or pick an agent that induction does not knock out.
Part 9: Special Populations
Pregnancy
Case-report data are too sparse to establish a drug-associated risk for birth defects, miscarriage or maternal and fetal outcomes. In animals, there were no malformations in rats and rabbits at up to 2.4 and 9.7 times the maximum human dose, and perinatal pup deaths rose at 4.9 times the dose in rats. Third-trimester exposure to any antipsychotic carries a risk of neonatal extrapyramidal and withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder).
- Framework: untreated schizophrenia, bipolar depression and MDD carry real risks to the mother and the pregnancy. If the patient is stable on lumateperone, weigh continuing against switching to an agent with more pregnancy data. Lumateperone clears within days, so the timing of a switch is easier than with cariprazine.
- Enroll patients in the National Pregnancy Registry for Atypical Antipsychotics (1-866-961-2388).
Lactation
A study of 17 lactating women who took one 42 mg dose found low levels in milk: an estimated infant dose of 0.0004 mg/kg/day, a relative infant dose of 0.06%. Aniline metabolites were not detectable in milk or plasma. There are no data on effects in the breastfed infant or on milk production, and this was a single dose, not steady state. Discuss it with the patient and watch the infant for sedation and feeding problems.
Fertility
Animal studies suggest lumateperone may impair male and female fertility. The label asks you to advise patients of reproductive potential.
Elderly
- Boxed warning applies. Do not use it for dementia-related psychosis outside a clearly justified, consented plan.
- Older patients carry more risk of orthostasis, falls and tardive dyskinesia (highest in older women), and SRI-associated hyponatremia if the combination is used.
- Trial data in people 65 and older are thin (Part 4).
Renal Impairment
No renal dose adjustment is labeled. See Part 4 for exposure numbers.
Hepatic Impairment
- Mild (Child-Pugh A): usual dose.
- Moderate (B) or severe (C): 21 mg once daily.
Pediatric / Adolescent
Safety and effectiveness have not been established, and antidepressant-class suicidality warnings apply in pediatric patients. Anything in this age group is off-label.
Part 10: Discontinuation and Taper
The label describes no discontinuation syndrome and no taper schedule. The terminal half-life is about 18 hours and steady state takes about 5 days, so the drug clears over days rather than weeks.
- Schizophrenia: the relapse-prevention study is the reason not to stop casually. In stable patients, relapse was more than twice as common after switching to placebo (38.6% vs 16.4% in Study 3).
- Bipolar depression and MDD: there is no randomized withdrawal data to guide duration, and the trials ran 6 weeks. Reassess once the episode has remitted and decide on clinical grounds.
- Stopping for side effects: sedation, dizziness and nausea resolve as the drug washes out. Watch for return of symptoms over the following weeks.
Part 11: Lumateperone vs the Alternatives
| Comparison | Lumateperone Advantage | Alternative Advantage |
|---|---|---|
| vs Lurasidone | No meal requirement and no titration; less akathisia; evidence in bipolar II depression as well as bipolar I | Generic and cheap; well-studied in bipolar depression and mixed features; also metabolically clean |
| vs Quetiapine | Much cleaner metabolic profile; less weight gain | Generic; anxiolytic when that is wanted; also covers bipolar I and II depression and mania |
| vs Cariprazine | Almost no akathisia; clears in days; no slow-titration trap | Covers mania and mixed episodes as well as depression; less sedation |
| vs Aripiprazole / Brexpiprazole (MDD add-on) | Akathisia and restlessness 1% in the add-on trials; no titration | Aripiprazole is generic and cheap, with the longer track record in MDD augmentation |
| vs Olanzapine / Risperidone (schizophrenia) | Weight, glucose, lipid and prolactin profile | Stronger evidence in acute psychosis; generic; lumateperone's PANSS effects are modest |
Lumateperone's niche is the patient who cannot afford metabolic, prolactin or movement side effects: a bipolar II patient who needs an antidepressant antipsychotic, a person with schizophrenia who gained weight on olanzapine, someone who stopped aripiprazole because of akathisia. It loses on price, on sedation, and on acute-psychosis potency.
The Bedside Cheat Sheet
What it is
- 5-HT2A antagonist with low D2 occupancy (39% at 42 mg), D2 partial agonist, moderate SERT binding
- Half-life ~18 h, steady state ~5 days; clears in days
- Schizophrenia; bipolar I/II depression (alone or with lithium/valproate); adjunctive MDD
- Not approved for mania, bipolar maintenance, children or dementia psychosis
Starting and dosing
- Capsules 42 / 21 / 10.5 mg, once daily, with or without food
- 42 mg from day one. No titration. 28 mg and 84 mg lost in trials
- Start at bedtime; a meal lowers the peak by a third
- Moderate 3A4 inhibitor: 21 mg. Strong: 10.5 mg. Child-Pugh B or C: 21 mg
- No serum levels to follow
Side effects that matter
- Sedation (12% to 24% vs 2% to 10%): bedtime dosing; counsel on driving
- Dizziness, nausea, dry mouth, headache
- Akathisia near placebo; EPS-type events near placebo except in MDD add-on (5% vs 0.8%); weight, glucose, lipids and prolactin flat in short trials
- Still monitor weight, glucose and lipids; the long-term data are uncontrolled
Don't forget
- Avoid CYP3A4 inducers (carbamazepine, phenytoin, rifampin, St. John's wort); rifampin cut AUC 98%
- Boxed: dementia-psychosis mortality and suicidality (antidepressant class)
- With an SSRI or SNRI: watch for serotonin syndrome and hyponatremia
- Brand-only and expensive; prior authorization is common
Before you write the script, check the medication list for CYP3A4 inducers and tell the patient to expect sleepiness.